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Abstract---The effects of Marcaine (bupivacaine) on RNA and protein synthesis in skeletal muscle have 
been studied. The drug did not affect RNA synthesis by pieces of rat tibialis anterior at concentrations 
as high as 0.5% (w/v), nor did it affect cell-free transcription of calf thymus DNA by wheat germ RNA 
polymerase I!. In contrast, Marcaine inhibited protein synthesis by muscle chunks, and also inhibited 
[:~H]leucine incorporation by cell-free components prepared from muscle. Specifically, the drug 
significantly inhibited aminoacylation of muscle transfer RN A with the amino acids leucine, methionine, 
lysine and valine (50-90 per cent) at a concentration of 0.5% and also inhibited elongation of 
polypeptide chains at the same concentration. Marcaine (0.5%) also inhibited aminoacylation of tRNA 
in cell-free systems derived from rat liver and from murine myeloma RPC-20, but it did not inhibit 
as strongly as in skeletal muscle. Interestingly, 0.5% Marcaine had no effect on the acylation of tRNA 
with leucine, methionine, lysine or valine when cell-free components from Escherichia coli were used. 
Marcaine (bupivacaine, d/-1-butylpipecoloxylidide) 
was introduced clinically as a local anesthetic in 
1963 [1]. Since that time, it has been shown to be a 
myotoxic agent, producing rapid degeneration of 
skeletal muscle fibers [2]. Most recently, this de- 
generative effect has been used to aid in skeletal 
muscle transplantation studies. Treatment of certain 
mammalian skeletal muscles with Marcaine, after 
removal of the muscle from the animal but prior to 
autogenous free grafting, results in a rapid degen- 
eration of the transplanted muscle followed by a 
regenerative phase in which the weight and con- 
tractile properties of the transplants are restored 
to levels which are 50-90 per cent those of control 
muscles [3, 4]. Max and Rifenberick[4l have also 
shown that the activities of several muscle enzymes 
decrease during the degenerative phase after Mar- 
caine treatment but increase during the subsequent 
regeneration after transplantation. These last results 
represent almost all the available data on the bio- 
chemical effects of Marcaine and essentially nothing 
is known of the direct effects of the drug at the 
biochemical level. It seemed advisable, therefore, to 
examine certain molecular aspects of Marcaine 
action in conjunction with its use in muscle trans- 
plantation studies. The experiments reported below 
were designed to examine the effects of Marcaine 
on protein and RNA synthesis in muscle. The effects 
of the drug on the incorporation of precursors into 
RNA and protein by muscle cells and by cell-free 
transcription and translation systems are described. 
MATERIALS AND METHODS 
Materials. Marcaine-HCl was generously sup- 
plied by Dr. F. C. Nachod (Sterling-Winthrop Re- 
search Institute, Rensselaer, New York) and was 
prepared as 5 or 10% (w/v) solutions in 50% 
ethanol. Laboratory rats weighing 200-250 g were 
used as a source of skeletal muscle. Minimal 
essential Eagle's medium minus leucine (MEM)was 
from Gibco, Grand Island, New York. [3H]leucine 
(58 Ci/m-mole), [asS]methionine (550 Ci/m-mole), 
[3H]methionine (6mCi/m-mole),  [aH]uridine (49 
Ci/m-mole) and [aH]UTP (45 Ci/m-mole) were from 
Amersham/Searle while [aH]lysine (38.9 Ci/m-mole) 
and [aH]valine (1.3 Ci/m-mole) were from New 
England Nuclear. Calf thymus DNA was from 
Sigma and Escherichia coli tRNA from Schwarz/ 
Mann. All other chemicals were reagent grade. 
Incubation of muscle chunks with [aH]uridine and 
[3H]leucme. Tibialis anterior was the muscle rou- 
tinely used in all the studies reported below. The 
muscles were removed from one or both hind limbs 
of a freshly killed rat, rinsed briefly in MEM and 
cut into chunks of about 1 mm a. Reaction mixtures 
for RNA or protein synthesis contained, per ml; 
MEM, 0.50 ml; a mixture of nonradioactive amino 
acids (alanine, asparagine, aspartic acid, glutamic 
acid, proline, serine and glycine), 0.10/zmole each; 
[3H]uridine (for RNA synthesis)or [3H]leucine (for 
protein synthesis), 10/zCi; Marcaine, 0.01 to 0.50% 
(w/v) final concentration, distilled water to 1 ml and 
two I mm 3 muscle chunks. The pH of each reaction 
mixture was adjusted to about 7.2 before adding the 
muscle. Reaction mixtures were incubated for 90 
min at 37 ° with shaking; the reactions were stopped 
by adding 10% trichloroacetic acid to the reaction 
vessels. Protein synthesis mixtures were then 
heated for 10 rain at 90 ° while those for RNA 
synthesis were placed on ice. The contents of the 
tubes was then collected on glass fiber filters, 
washed thoroughly with 10% trichloroacetic acid 
and ethanol-ether ( I : 1, v/v) and dried. The precipi- 
tates were removed from the filters by heating in 
1 ml of 0.5 N NaOH for 30 min at 90 °. Aliquots of 
the NaOH digests were removed for liquid scintil- 
lation counting and protein determination. Results 
of these experiments are expressed as cpm incor- 
porated/mg of total protein. 
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Preparation of  muscle tRNA,  soluble enzymes and 
polysomes. For  the preparat ion of componen t s  for 
aminoacyla t ion and cell-free protein synthesis ,  
minced tibialis was homogenized  in 2.5 vol. medium 
A [5] containing 0.25 M sucrose,  using a Polytron 
tissue homogenizer  at a setting of 45 V. t R N A  and 
soluble enzymes  were  prepared f rom a port ion of 
this homogena te  as descr ibed previously  [5]. t R N A  
and enzymes  were  prepared f rom rat l iver and 
murine myeloma RPC-20 homogenates  in a similar 
fashion [5]. E. coli acylat ing enzyme  was prepared 
as descr ibed by Muench  and Berg [6]. 
Polysomes  were  prepared f rom a supernatant  
f ract ion result ing f rom low speed centr i fugat ion of 
the muscle homogena te  [5]. The supernatant  frac- 
tion was brought to 1.2% with Nonidet  P-40 and 
al lowed to stand in ice for 10 min. Polysomes  were  
col lected by layering the detergent- t rea ted  super- 
natant f ract ion over  5-ml cushions of  medium A 
containing 1.1 M sucrose  and centr i fuging for  2 to 
2.5 hr at 203,000 g. Polysome pellets were  resus- 
pended in medium A containing 0.25 M sucrose  and 
general ly used immediate ly  for  protein synthesis.  
Conditions for cell-free aminoacylation, trans- 
lation and transcription. Aminoacyla t ion  of  t R N A  
was carried out  in 100-/zl react ion mixtures  con- 
taining: Tris-HC1,  pH 7.6, 50 mM:  MgC12, 10 mM;  
ATP,  2.5 mM;  2-mercaptoethanol ,  5 raM: [:~H]- or 
[3"~S]amino acid, 50 #Ci /ml ;  muscle t R N A ,  0.35 to 6 
Az~0/ml, or rat l iver tRNA,  6.2 to 15.6 A260/ml; or 
mye loma  RPC-20 tRNA,  3.2 to 16 A2n0/ml or E. coli 
t R N A ,  8 A2~0/ml and acylat ing enzyme ,  1.2 to 4.3 
mg/ml.  React ion mixtures  were  incubated for 10 min 
at 37 ° and analyzed as descr ibed previously [5]. 
Results  are expressed  as cpm amino acid 
acylated/Az60 unit of  added tRN A. Large scale (2 ml) 
react ion mixtures  were  cons t ruc ted  to prepare 
[:~'~S]methionyl-tRNA f rom muscle and the acylated 
t R N A  was isolated as descr ibed previously  [7]. 
React ion mixtures  (100/zl) for protein synthesis  
contained:  T r i s -HCl ,  pH 7.6, 5 0 m M ;  MgCI2, 10 
mM;  KC1, 80 raM, 2-mercaptoethanol ,  5 raM; ATP,  
5 m M ;  GTP,  0 . 5 m M ;  phosphocrea t ine ,  10mM;  
creat ine phosphokinase ,  0.2 mg/ml:  nineteen non- 
radioact ive  amino acids, 0.1 mM each;  [aH] leucine,  
50 #Ci /ml ;  soluble enzymes ,  0.6 mg/ml and poly- 
somes,  0.24 to 1.2 A26Jml. In some exper iments ,  
[:3'~S]methionyl-tRNA was present  rather than [:~H]- 
leucine,  and [ '2C]leucine was added to those 
react ion mixtures  to give a final concent ra t ion  of  
0.1 raM. React ion mixtures  were  incubated for  
20 min at 37 ° and were  analyzed as descr ibed pre- 
viously [5, 71. Results  are expressed  as cpm amino 
acid incorporated/A26,, unit of  po lysomes  added. 
React ion mixtures  for R N A  synthesis  (100 #1) 
were  as descr ibed previous ly  [8] except  that all four  
nucleoside t r iphosphates  were  present  at 0.1 mM 
final concentra t ions .  Wheat  germ R N A  polymerase  
I1 [9] was the enzyme  source,  calf  thymus D N A  was 
the terfiplate and [3H]UTP was the labeled triphos- 
phate. Results  are expressed  as nmoles [:~H]UMP 
incorporated/100-#l  react ion mixture.  
Protein was de termined  by the method of  Lowry  
et al,[10] or by the method  of  Warburg and 
Christ ian [11]. 
RESULTS 
Effects of  Mareaine on RNA synthesis. Marcaine 
(0.01 to 0.50% final concn) was added to reaction 
mixtures  (prepared as descr ibed above)  containing 
pieces of rat tibialis anterior.  Although good incor- 
porat ion of [:3H]uridine into R N A  was observed ,  no 
effect  of Marcaine on this incorporat ion could be 
de tec ted  (data not shown). The results presented 
below for protein synthesis  indicate that Marcaine 
can penetra te  muscle fibers; however ,  it seemed 
possible that the failure to observe  any effect of 
Marcaine on transcript ion in muscle chunks might 
be due to its inability to penetra te  the nuclear mem- 
brane of the muscle cells. To  el iminate this possi- 
bility, the effect  of the drug on transcript ion under 
cel l-free condi t ions  was examined.  No  at tempt  was 
made in this study to isolate muscle R N A  poly- 
merase;  however ,  the polymerase  used, f rom wheat  
germ,  has been shown to be similar in propert ies to 
o ther  eukaryot ic  RN A polymerases  [9, 12]. The  data 
of  Table  1 confirm the results descr ibed above  in 
demonst ra t ing  that Marcaine has no effect on cell- 
f ree transcript ion at concent ra t ions  as high as 0.50% 
(0.015 M). A slight inhibition of R N A  synthesis  by 
1.0% Marcaine was observed  in the exper iments  of 
Table 1, but this effect  was not consistent ly ob- 
served in o ther  cell-free t ranscript ion studies. Thus,  
both in vivo and in vitro studies suggest that Mar- 
caine has no effect  on R N A  synthesis.  It should be 
noted that, in all the studies descr ibed herein,  
appropr ia te  controls  were per formed to el iminate 
any possible art ifacts resulting f rom the effects  of 
ethanol  on R N A  and protein synthesis.  
Effects of  Mareaine on protein synthesis. Figure 
1 depicts  the effects  of  Marcaine on [:~Hlleucine 
incorporat ion into protein by muscle chunks.  As can 
be seen, inhibition of leucine incorporat ion is 
observed  at Marcaine concent ra t ions  as low as 
0.01% and incorporat ion is complete ly  abolished at 
0.50% Marcaine.  The  data  presented  in the preced- 
ing section el iminate the possibility that Marcaine 
Table 1. Effects of Marcaine on transcription 
of calf thymus DNA by wheat germ RNA 
polymerase II* 
[:~H]UMP 
Marcaine concn incorporated into RNa 









* Incubation and assay conditions were as 
described in Materials and Methods and in 
Ref. 8. One nmole [3H]UMP incorporated is 
equivalent to 222,320 cpm. All experimental 
values were corrected by subtracting a zero 
time control. Wheat germ RNA polymerase 
II [9] was present at a concentration of 3.2 
mg/ml. 
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Fig. 1. Effects of Marcaine on protein synthesis by rat 
skeletal muscle pieces. Incubation and assay conditions 
were as described in Materials and Methods. Zero time 
controls were subtracted from experimental data. These 
and all other incorporation assays were performed in 
duplicate. 
inhibits translation by first inhibiting transcription, 
but the possibility remained that the results obtained 
in the experiments of Fig. 1 were due to the effects 
of the drug on some other essential process, such 
as oxidative phosphorylation. To eliminate this 
possibility, cell-free components for protein syn- 
thesis were prepared and the effects of the drug on 
cell-free translation were studied. Figure 2 shows 
that Marcaine still inhibited [3H]leucine incorpora- 
tion in a cell-free system. Inhibition of 11 per cent 
was observed at 0.10% Marcaine while the level of 
inhibition was 70 per cent at 0.50% Marcaine. 
The process of protein biosynthesis is a complex 
one, and many individual biochemical events con- 
tribute to the synthesis of one peptide bond. It was 
of interest, therefore, to determine whether Mar- 
caine inhibited protein synthesis generally, in a non- 














O. 25 0 50 
M o r c a i n e ,  ° / .  W / V  
Fig. 2. Effects of Marcaine on cell-free protein synthesis 
using components from rat skeletal muscle. Conditions for 
cell-free protein synthesis were described in Materials and 
Methods. Data were treated as in the legend to Fig. 1. 
reaction of protein synthesis was the major target 
for the action of Marcaine. In the present study, the 
effects of the drug on activation and elongation 
reactions have been examined. Table 2 shows the 
effects of the drug on the esterification of muscle 
tRNA with ieucine. It is evident that Marcaine did 
inhibit the acylation reaction in a concentration- 
dependent fashion (Table 2). The inhibition could 
not be overcome by increasing the amount of tRNA 
in the reaction mixture (data not shown), but inhi- 
bition was relieved by doubling the amount of 
enzyme used (Table 2). 
In view of the results just described, it was of 
interest to examine the effects of Marcaine on the 
aminoacylation reaction more thoroughly. To this 
end, tRNA and acylating enzymes from rat liver, 
mouse myeloma RPC-20 and E. coli were prepared. 
Acylation of muscle, liver, myeloma and bacterial 
tRNA with the amino acids leucine, methionine, 
lysine and valine was performed in the presence and  
absence of Marcaine. The results of these experi- 
ments, shown in Table 3, allow several conclusions 
to be drawn. First, 0.5% Marcaine strongly inhibited 
acylation of tRNA with leucine in all three eukary- 
otic cell-free systems tested. Acylation with the 
other three amino acids was inhibited less severely 
than acylation with leucine. Second, although the 
degree of inhibition varied depending on which of 
the four amino acids was being used, 0.5% Marcaine 
was more effective in inhibiting acylation of muscle 
tRNA than t R N A  from rat liver, and was more 
inhibitory to the acylation of liver tRNA than tRNA 
from the mouse myeloma. These results suggest that 
Marcaine may have some specificity for the charging 
system from skeletal muscle. Third, 0.5% Marcaine 
was completely ineffective in inhibiting acylation of 
tRNA from E. coli. 
In order to examine the effects of the drug on 
polypeptide chain elongation, it was necessary to 
utilize conditions for cell-free protein synthesis in 
which possible inhibition of the activation and in- 
itiation reactions could be minimized. Effects of 
Marcaine on the activation reaction were avoided 
by performing the protein synthesis reactions with 
preacylated tRNA. tRNA acylated with high specific 
activity [3~S]methionine was prepared as described 
in Materials and Methods and in Ref. 7. The 
[3"~S]methionyl-tRNA was then utilized in a cell-free 
reaction system, prepared as described in Materials 
Table 2. Effects of Marcaine on aminoacylation of muscle 
tRNA with [aH]leucine* 
[3H]leucine 
Marcaine concn Enzyme concn A2~o tRNA 
(%, w/v) (mg/ml) (cpm) 
0 1.2 51,400 
0.10 1.2 25,100 (49) 
0.50 1.2 2,940 (94) 
0.0 2.4 142,940 
0.50 2.4 56,740 (60) 
* Aminoacylation conditions were as described in 
Materials and Methods. Experimental values were cor- 
rected by subtracting zero time controls, and figures in 
parentheses represent per cent inhibition by Marcaine. 
a.P. 2 7 / 1 3 - - - D  
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Table 3. Effects of Marcaine on the acylation of tRNA with various amino acids* 
Amino acid acylated/A~,, tRNA 
(cpm) 
Acylating 
system Leucine Methionine Lysine Valine 
Rat muscle 172,000 49,600 48,900 4,600 
Rat muscle + Marcaine 300(90) 25.500(45) 8,600(82) 2,000(57) 
Rat liver 98,700 16,900 233,900 20,500 
Rat liver + Marcaine 7,800(92) I 1,200(34) 114,800(51) 13,900(32) 
Mouse myeloma 635,500 39,800 536,400 44.700 
Mouse myeloma+ Marcaine 1 I 1,300(82) 36,900(7) 427,500(20) 31,500(30) 
E. coli 484,700 171,000 353,600 28,800 
E. coil + Marcaine 567,900(0) 185,000(0) 453,600 (0) 33,800(0) 
* Acylation of tRNA was performed as described in Materials and Methods. All reaction 
mixtures contained about 3 mg/ml of acylating enzyme. Data in the table have been treated 
as described in the legend to Table 2 and numbers in parentheses represent per cent 
inhibition by Marcaine. 
Table 4. Effects of Marcaine on polypeptide chain 




Marcaine concn polysomes 
(%, w/v) (cpm) 
1 0 3190 
0.50 2800(12) 
II 0 3050 
0.50 2040 (33) 
* Procedures for preparation of pS]methionyl-tRNA 
and for cell-free protein synthesis were as described in 
Materials and Methods. Incubation mixtures contain 
10 ~ cpm/ml of [35S]methionyl-tRNA. Data were treated as 
described in the legend to Table 2. 
and Methods ,  but containing [ ' "C]methionine to pre- 
vent  reacylat ion of  the muscle  t R N A  during protein 
synthesis .  To  el iminate possible effects  of  Marca ine  
on the initiation react ions ,  cel l -free incubat ions 
were  pe r fo rmed  at 10 mM Mg 2+ and at 37 °. Both 
these values are well above  the opt ima for  physio- 
logical initiation of protein synthesis  in eukaryot ic  
sys tems[13,  14]. Resul ts  of  exper iments  using 
[3"~S]methionyl-tRNA as the source  of  labeled amino 
acid are repor ted  in Table  4. It is obvious  that the 
levels  of  amino  acid incorporat ion are lower  in Table  
4 than in Fig. 2 even  though the methionine  used has 
a higher specific act ivi ty  than the leucine.  This 
dif ference results f rom the fact  that much less total 
amino  acid was added to the react ion mixtures  as 
[3'~S]methionyl-tRNA than was added as [aH]leucine. 
Significant [35S]methionine incorporat ion was ob- 
served never the less  in the exper iments  of  Table  4, 
and it can be  seen that, in two separate  exper iments ,  
Marcaine  at 0,50 per cent  inhibited this incorpor-  
ation by about  23 per cent  on the average.  
DISCUSSION 
The results  presented  above  demons t ra te  direct ly 
that Marcaine ,  while wi thout  effect on R N A  syn- 
thesis,  does  inhibit protein synthesis  in muscle .  At 
a concent ra t ion  of  0.50% (0.015 M), the drug inhi- 
bited overall  amino acid incorporat ion,  act ivat ion 
and elongat ion in a cel l-free system. The maximum 
concent ra t ion  of  Marcaine used in most of these 
studies (0.50%) was chosen to cor respond to the 
concent ra t ion  of  commerc ia l ly  available Marcaine 
used in skeletal muscle transplantat ion studies. 
H o w e v e r ,  the data  of Figs. I and 2 and Table 2 
indicate that lower concent ra t ions  of Marcaine are 
effect ive  in inhibiting overall  protein synthesis  and 
aminoacyla t ion.  
It will be noted in compar ing  the data  of  Figs. 1 
and 2 above  that 0.50% Marcaine  produced a greater  
degree  of  inhibition of protein synthesis  in muscle 
chunks than in a cel l-free sys tem der ived f rom the 
same muscle.  The reason for  this d iscrepancy is not 
clear ,  but it seems possible,  if not likely, that the 
drug affects other  biochemical  pa thways  (oxidat ive 
phosphoryla t ion,  for example)  whose  activit ies may 
be essential  for  cont inued protein synthesis  in intact 
muscle.  Because  of  this possibility, an invest igat ion 
of  the effects  of  the drug on mitochondrial  funct ion 
and on the enzymat ic  pathways  involved  in nucleo- 
side t r iphosphate  biosynthesis  and inter-conver-  
sion would be illuminating. 
The  data of  Tables  3 and 4 indicate that Marcaine 
affects both the act ivat ion and elongat ion react ions 
of  protein synthesis  and that the degree of inhibition 
of  aminoacyla t ion  was higher than for e longat ion 
under the assay condi t ions  employed .  In addit ion,  
the data of  Table  2 suggest  a direct  effect  of the drug 
on the a m i n o a c y l - t R N A  synthetase  since an 
increase in the concent ra t ion  of enzyme  in the reac- 
tion mixture  led to decreased  inhibition of  amino- 
acylat ion by Marcaine.  An increase in t R N A  
concent ra t ion  was without  effect.  
The fact  that Marcaine was a less effect ive in- 
hibitor of  aminoacyla t ion  of t R N A  f rom rat l iver  and 
mouse mye loma  than t R N A  from muscle suggests 
that the drug possesses  some specificity for the 
acylat ion apparatus f rom skeletal muscle.  Kinet ic  
studies on the inhibition of  [3H]leucine acylat ion are 
in progress  to ver i fy  this hypothesis .  Perhaps the 
most  interest ing observa t ion  regarding the effect  of  
Marcaine  on aminoacyla t ion was its comple te  
inability to inhibit the acylat ion of  E. c o l i t R N A  with 
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the  four  a m i n o  ac ids  t es ted .  Indeed ,  Marca ine  
s t imula ted  the  acy la t ion  of  E. coli  t R N A  with  all 
four  a m i n o  acids  (Table  3). T he  m e c h a n i s m  of  this  
s t imula t ion  is u n k n o w n  at this  t ime.  T he  s tud ies  
p r e sen t ed  here  shou ld  be  e x t e n d e d  to o t h e r  pro- 
ka ryo te s  and  o t h e r  a m i n o  acids  shou ld  also be 
t es ted ,  but  the  da ta  of  Tab le  3 sugges t  tha t  Marca ine  
may  be long  to the  g roup  of  t r ans la t iona l  inh ib i tors  
specific for  the  p ro te in  syn the t i c  a p p a r a t u s  of  
euka ryo te s .  
W e  have  not  yet e x a m i n e d  the  ef fec ts  of  the  drug  
on the ini t ia t ion r eac t ions  of  p ro te in  syn thes i s ,  but  
none  of  the  cel l - f ree  s tudies  de sc r ibed  was per- 
f o r m e d  u n d e r  cond i t i ons  f avo r ing  physio logica l  ini- 
t iat ion.  It s eems  likely,  t he re fo re ,  tha t  the  resu l t s  of  
Tab les  2-4  are sufficient  to expla in  the  inhib i t ion  of  
overa l l  a m i n o  acid i nco rpo ra t i on  o b s e r v e d  in Fig. 2. 
In conc lus ion ,  it s e e m s  qui te  l ikely tha t  the  inhibi-  
tory  ef fec ts  of Marca ine  on pro te in  syn thes i s  make  
a s ignif icant  c o n t r i b u t i o n  to the  o b s e r v e d  degener -  
a t ion of  M a r c a i n e - t r e a t e d  skeleta l  musc le  a f t e r  
t r ansp l an t a t i on .  
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